National Energy Services Reunited Corp. Ordinary Shares
NESRNational Energy Services Reunited Corp. (NESR) is an upstream oilfield services company providing a range of integrated drilling, production, and well intervention solutions. Operating primarily in the Middle East, North Africa, and Asia-Pacific regions, NESR supports oil and gas exploration, development, and production activities with services including well testing, pressure pumping, and fluid management. The company aims to deliver comprehensive energy services that enhance operational efficiency and reduce environmental impact.
Company News
Director Yousif Mohammed Ali Nasser Al-Nowais sold 1,919,594 shares (89.33% of his holdings) of National Energy Services Reunited Corp. (NESR) for $51.5 million on June 25, 2026, following a 363.6% year-over-year stock surge. While insider selling after significant gains can raise questions, the article cautions against over-interpreting such mov...
National Energy Services Reunited (NESR) stock surged nearly 8% after the company announced it secured approximately $300 million in new cementing contracts with clients in Kuwait and North Africa. The deals represent a significant win for the oilfield services company, with last year's total revenue at $1.3 billion, and demonstrate the company's...
GeoSphere Capital Management acquired 1,385,000 shares of Borr Drilling (valued at $5.58 million) in Q4 2025, representing 1.84% of the fund's assets. The investment reflects renewed confidence in the offshore drilling sector as contract activity recovers and Borr's stock has surged 95% over the past year. Success depends on sustaining higher day...
Saudi Arabia's facility management market is expected to grow from USD 51.23 billion in 2025 to USD 134.82 billion by 2035 at a 10.16% CAGR, driven by giga-projects transitioning to operations, tourism expansion, industrial growth, and infrastructure development under Vision 2030. Soft services dominate with 74.33% market share, while outsourcing...
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its EDP1815 Phase 2 trial, in which the primary endpoint was not met. ContraFect Corporation (NASDAQ: CFRX) gained 87% to $2.4693. ContraFect said first pat...
